Summary
Vertex Pharmaceuticals Inc. (VRTX) reported strong financial performance for the fiscal year ending December 30, 2024, with net product revenues reaching $11.0 billion, a 12% increase year-over-year, driven primarily by robust global demand for its cystic fibrosis (CF) medicine, TRIKAFTA/KAFTRIO, and successful label expansions. The company expanded its CF portfolio with the FDA approval of ALYFTREK in December 2024, a once-daily triple combination therapy that demonstrates non-inferiority to TRIKAFTA and offers improved sweat chloride levels. Vertex also saw its TRIKAFTA label expand to include 94 additional CFTR mutations, broadening patient eligibility. Beyond CF, Vertex made significant strides in other therapeutic areas, including the U.S. FDA approval of JOURNAVX in January 2025 for moderate-to-severe acute pain, and continued progress with CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, with over 50 authorized treatment centers activated globally. The company continues to invest heavily in its diverse pipeline, with advancements in programs for APOL1-mediated kidney disease, IgA nephropathy, Type 1 Diabetes, and various pain indications. Despite increased operating expenses due to R&D investments and commercial launches, Vertex maintains a strong financial position, though its cash reserves saw a decrease following the acquisition of Alpine Immune Sciences and share repurchases.
Financial Highlights
49 data points| Revenue | $11.02B |
| Cost of Revenue | $1.53B |
| Gross Profit | $9.49B |
| SG&A Expenses | $1.46B |
| Operating Expenses | $11.25B |
| Operating Income | -$232.90M |
| Net Income | -$535.60M |
| EPS (Basic) | $-2.08 |
| EPS (Diluted) | $-2.08 |
| Shares Outstanding (Basic) | 257.90M |
| Shares Outstanding (Diluted) | 257.90M |
Key Highlights
- 1Net product revenues increased by 12% to $11.0 billion in 2024, primarily driven by TRIKAFTA/KAFTRIO.
- 2FDA approval of ALYFTREK in December 2024 for cystic fibrosis, expanding the company's CF medicine portfolio.
- 3TRIKAFTA's label expanded in December 2024 to include 94 additional non-F508del CFTR mutations, increasing patient eligibility.
- 4Received FDA approval for JOURNAVX in January 2025 for moderate-to-severe acute pain, marking its entry into the pain market.
- 5CASGEVY, a gene-editing therapy for sickle cell disease and beta thalassemia, has seen global uptake with over 50 authorized treatment centers activated.
- 6Significant investment in R&D, including the acquisition of Alpine Immune Sciences, contributing to a diverse pipeline across multiple therapeutic areas.
- 7Total operating costs and expenses increased by 86% due to substantial investments in R&D, commercial launches, and the Alpine acquisition.